A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
NCT ID: NCT02969382
Last Updated: 2024-07-05
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
245 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-12-05
Study Completion Date
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
NCT04072354
Schizophrenia
COMPLETED
PHASE3
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
NCT05628103
Schizophrenia
COMPLETED
PHASE3
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
NCT04109950
Schizophrenia
TERMINATED
PHASE3
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
NCT01994473
Schizophrenia
COMPLETED
PHASE1
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
NCT01940159
Schizophrenia
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, randomized, double-blind, parallel-group, flexibly-dosed, study evaluating the efficacy and safety of SEP-363856 in acutely psychotic adult subjects with schizophrenia using SEP-363856 (50 or 75 mg/day \[ie, once daily\]) versus placebo over a 4-week treatment period. Primary hypoathesis to be tested: H0: μSEP = μPBO versus H1: μSEP ≠ μPBO, where μSEP and μPBO are the mean changes from Baseline at Week 4 in PANSS total score for the SEP-363856 and placebo arms, respectively. Subjects who complete study SEP361-201 may be eligible to enroll in the open-label extension study SEP361-202.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Schizophrenia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SEP-363856
SEP-363856 capsule (50 mg or 75 mg) once daily
Group Type
EXPERIMENTAL
SEP-363856
Intervention Type
DRUG
One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
Placebo
Placebo capsule once daily
Group Type
PLACEBO_COMPARATOR
Placebo - Cap
Intervention Type
DRUG
One Placebo capsule daily for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SEP-363856
One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
Intervention Type
DRUG
Placebo - Cap
One Placebo capsule daily for 4 weeks
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject must give written informed consent and privacy authorization prior to participation in the study. Separate consent will be obtained from a caregiver or legal guardian if required by local law.
2. Subject must be willing and able to comply with the study procedures and visit schedules, including required hospitalization for the washout period and the double-blind treatment period, and must be able to understand and follow verbal and written instructions.
3. Male or female subject between 18 to 40 years of age (inclusive) at the time of consent.
4. Subject meets DSM-5 criteria for schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the SCID-CT). The duration of the subject's illness whether treated or untreated must be ≥ 6 months.
5. Subject must have a CGI-S score ≥ 4 (moderate or greater) at screening and Baseline (Day 1).
6. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at screening and Baseline (Day 1).
7. Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months).
• Subject has marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.
• Subject requires hospitalization for an acute psychotic exacerbation at the time of screening or has been hospitalized for the purpose of treating an acute psychotic exacerbation for no more than 2 consecutive weeks immediately before screening.
Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to an acute psychotic exacerbation may be included if such a hospitalization was for a condition other than an acute psychotic relapse. For example, subjects in a long-term hospital setting who have an acute exacerbation and are transferred to an acute unit are eligible for the study.
8. Subject has had no more than 2 prior hospitalizations for the treatment of an acute exacerbation of schizophrenia (not including the current hospitalization) This history must be confirmed based on report by a reliable informant (eg., caregiver or family member) or medical records available at the time of screening.
9. Subject's BMI must be at least 18 kg/m2 but no more than 35 kg/m2.
10. Female subject must have a negative serum pregnancy test at screening.11. Female subject of reproductive potential agrees to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken. In the Investigator's judgment, the subject will adhere to this requirement.
1. Adequate contraception is defined as continuous use of either two barrier methods (eg, condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive.
Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening.
2. Subjects who are of non-reproductive potential, ie, subject who is surgically sterile, has undergone tubal ligation, or is postmenopausal (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis) are not required to remain abstinent or use adequate contraception.
11. Female subject of reproductive potential agrees to remain abstinent or use highly effective and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken (See Section 21 Appendix II Highly Effective Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 36 17 August 2017 Contraceptive procedures). In the Investigator's judgment, the subject will adhere to this requirement.
12. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use highly effective methods of birth control (outlined in Section 21) from screening until at least 30 days after the last study drug administration.
13. Subject must be able and agree to remain off prior antipsychotic medication for the duration of the study.
14. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
15. Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin).
16. Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (eg, due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.
17. Subject must agree to comply with all restrictions for the required length of time
2. Subject must be willing and able to comply with the study procedures and visit schedules, including required hospitalization for the washout period and the double-blind treatment period, and must be able to understand and follow verbal and written instructions.
3. Male or female subject between 18 to 40 years of age (inclusive) at the time of consent.
4. Subject meets DSM-5 criteria for schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the SCID-CT). The duration of the subject's illness whether treated or untreated must be ≥ 6 months.
5. Subject must have a CGI-S score ≥ 4 (moderate or greater) at screening and Baseline (Day 1).
6. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at screening and Baseline (Day 1).
7. Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months).
• Subject has marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.
• Subject requires hospitalization for an acute psychotic exacerbation at the time of screening or has been hospitalized for the purpose of treating an acute psychotic exacerbation for no more than 2 consecutive weeks immediately before screening.
Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to an acute psychotic exacerbation may be included if such a hospitalization was for a condition other than an acute psychotic relapse. For example, subjects in a long-term hospital setting who have an acute exacerbation and are transferred to an acute unit are eligible for the study.
8. Subject has had no more than 2 prior hospitalizations for the treatment of an acute exacerbation of schizophrenia (not including the current hospitalization) This history must be confirmed based on report by a reliable informant (eg., caregiver or family member) or medical records available at the time of screening.
9. Subject's BMI must be at least 18 kg/m2 but no more than 35 kg/m2.
10. Female subject must have a negative serum pregnancy test at screening.11. Female subject of reproductive potential agrees to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken. In the Investigator's judgment, the subject will adhere to this requirement.
1. Adequate contraception is defined as continuous use of either two barrier methods (eg, condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive.
Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening.
2. Subjects who are of non-reproductive potential, ie, subject who is surgically sterile, has undergone tubal ligation, or is postmenopausal (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis) are not required to remain abstinent or use adequate contraception.
11. Female subject of reproductive potential agrees to remain abstinent or use highly effective and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken (See Section 21 Appendix II Highly Effective Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 36 17 August 2017 Contraceptive procedures). In the Investigator's judgment, the subject will adhere to this requirement.
12. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use highly effective methods of birth control (outlined in Section 21) from screening until at least 30 days after the last study drug administration.
13. Subject must be able and agree to remain off prior antipsychotic medication for the duration of the study.
14. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
15. Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin).
16. Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (eg, due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.
17. Subject must agree to comply with all restrictions for the required length of time
Exclusion Criteria
1\. Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at or during the Screening period (ie, in the past one month) and/or at Baseline (ie, since last visit).
2\. Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
3\. Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 6 months prior to signing the informed consent, or has participated in 2 or more studies within 24 months prior to signing informed consent.
4\. Subject has previously received SEP-363856. 5. Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
1. Hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease that is clinically significant or unstable (except for untreated, asymptomatic, seasonal allergies at time of dosing).
2. Subject has a history of neuroleptic malignant syndrome. Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 37 17 August 2017
3. Subject has a history of malignancy within 5 years prior to the Screening visit, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
4. Disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection, or any surgical procedure) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
5. Subject has Alcohol or Substance Abuse Disorder (DSM-5 criteria). The only exceptions include caffeine or nicotine.
6. Subject has a clinically significant abnormal 12-lead ECG that may jeopardize the subject's ability to complete the study or a screening 12-lead ECG demonstrating any one of the following: heart rate \> 100 beats per minute, QRS \> 120 ms, QT interval corrected for heart rate using Fridericia's formula (QTcF) \> 450 ms (males), QTcF \> 470 ms (females), or PR \> 220 ms.
7. Subjects with known history of human immunodeficiency virus (HIV) seropositivity.6. 6. Female subject who is pregnant or lactating.
7\. Subject who has a lifelong history or presence of symptoms consistent with a major psychiatric disorder other than schizophrenia as defined by DSM-5. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, major depressive disorder, bipolar depression, mania, schizoaffective disorder, obsessive compulsive disorder, posttraumatic stress disorder. Previous or current symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment.
8\. Subject tests positive for drugs of abuse at screening, however, a positive test for amphetamines, barbiturates, opiates, benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s). In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this substance during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
9\. Subject is at significant risk of harming self, others or objects based on the Investigator's judgment.
10\. Subject has attempted suicide within 3 months prior to screening. 11. Subject is involuntarily hospitalized. 12. Subject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer), prior to the screening phase.
13\. Subject is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents, given at adequate dose for at least 4 weeks within a 1 year period prior to Screening.
14\. Subject has a history of treatment with clozapine for refractory psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of Screening.
15\. Subject is receiving a total dose of antipsychotic medication equivalent to \> 12.0 mg/day of haloperidol at Screening (see Section 22, Appendix III for table of haloperidol dose equivalents). Subject may be eligible if such treatment is less than 2 weeks in duration after consultation with the Medical Monitor.
16\. Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require ECT during the study.
17\. Subject takes or has taken other disallowed recent or concomitant medications (see Section 10.3). Subjects must taper off antipsychotic medications by Day -1.
18\. Subject has a history of allergic reaction or suspected sensitivity to any substance that is contained in the formulation (gelatin).
19\. Subject has any clinically significant abnormal laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin (Note: abnormal findings that may be clinically significant or of questionable significance will be discussed with the Medical Monitor prior to including subject).
20\. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.
Note: Subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, the subject will be excluded.
21\. Subject has a serum blood urea nitrogen (BUN) or serum creatinine (Cr) value ≥ 1.5 times the upper limit of normal for the reference range.
22\. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
23\. Subject has used disallowed prescription or disallowed nonprescription drugs, vitamins, or dietary or herbal supplements within 14 days prior to dosing or anticipates the need for any disallowed medication during their participation in this study \[exception: female subjects who are taking oral, patch, or intrauterine device (IUD) hormonal contraceptives, or progestin implant or injection\].
24\. Subject is a staff member or the relative of a staff member. 25. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or HbA1c ≥ 6.5% will be excluded.
26\. Subject has a prolactin concentration \> 100 ng/mL at screening or has a history of pituitary adenoma. NOTE: Subjects with prolactin levels \> 100 ng/mL and ≤ 200 ng/mL Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 39 17 August 2017 at the Screening visit are permitted to enroll after discussion with the Medical Monitor to ensure exclusion of non-psychotropic drug-related causes of elevated prolactin levels.
27\. .Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Randomization Criteria
1. Subject must have a PANSS total score ≥ 80 at Baseline (Day 1).
2. Subject must have a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at Baseline (Day 1).3. Subject must have a CGI-S score ≥ 4 at Baseline (Day 1).
3. Subject must not demonstrate a decrease (improvement) of ≥ 20% in the PANSS total score between Screening and Baseline visits, or the PANSS total score falls below 80 at Baseline (Day 1).
4. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
5. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
6. Subject must not answer "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Baseline (ie, since last visit).
2\. Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
3\. Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 6 months prior to signing the informed consent, or has participated in 2 or more studies within 24 months prior to signing informed consent.
4\. Subject has previously received SEP-363856. 5. Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
1. Hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease that is clinically significant or unstable (except for untreated, asymptomatic, seasonal allergies at time of dosing).
2. Subject has a history of neuroleptic malignant syndrome. Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 37 17 August 2017
3. Subject has a history of malignancy within 5 years prior to the Screening visit, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
4. Disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection, or any surgical procedure) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
5. Subject has Alcohol or Substance Abuse Disorder (DSM-5 criteria). The only exceptions include caffeine or nicotine.
6. Subject has a clinically significant abnormal 12-lead ECG that may jeopardize the subject's ability to complete the study or a screening 12-lead ECG demonstrating any one of the following: heart rate \> 100 beats per minute, QRS \> 120 ms, QT interval corrected for heart rate using Fridericia's formula (QTcF) \> 450 ms (males), QTcF \> 470 ms (females), or PR \> 220 ms.
7. Subjects with known history of human immunodeficiency virus (HIV) seropositivity.6. 6. Female subject who is pregnant or lactating.
7\. Subject who has a lifelong history or presence of symptoms consistent with a major psychiatric disorder other than schizophrenia as defined by DSM-5. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, major depressive disorder, bipolar depression, mania, schizoaffective disorder, obsessive compulsive disorder, posttraumatic stress disorder. Previous or current symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment.
8\. Subject tests positive for drugs of abuse at screening, however, a positive test for amphetamines, barbiturates, opiates, benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s). In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this substance during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
9\. Subject is at significant risk of harming self, others or objects based on the Investigator's judgment.
10\. Subject has attempted suicide within 3 months prior to screening. 11. Subject is involuntarily hospitalized. 12. Subject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer), prior to the screening phase.
13\. Subject is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents, given at adequate dose for at least 4 weeks within a 1 year period prior to Screening.
14\. Subject has a history of treatment with clozapine for refractory psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of Screening.
15\. Subject is receiving a total dose of antipsychotic medication equivalent to \> 12.0 mg/day of haloperidol at Screening (see Section 22, Appendix III for table of haloperidol dose equivalents). Subject may be eligible if such treatment is less than 2 weeks in duration after consultation with the Medical Monitor.
16\. Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require ECT during the study.
17\. Subject takes or has taken other disallowed recent or concomitant medications (see Section 10.3). Subjects must taper off antipsychotic medications by Day -1.
18\. Subject has a history of allergic reaction or suspected sensitivity to any substance that is contained in the formulation (gelatin).
19\. Subject has any clinically significant abnormal laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin (Note: abnormal findings that may be clinically significant or of questionable significance will be discussed with the Medical Monitor prior to including subject).
20\. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.
Note: Subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, the subject will be excluded.
21\. Subject has a serum blood urea nitrogen (BUN) or serum creatinine (Cr) value ≥ 1.5 times the upper limit of normal for the reference range.
22\. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
23\. Subject has used disallowed prescription or disallowed nonprescription drugs, vitamins, or dietary or herbal supplements within 14 days prior to dosing or anticipates the need for any disallowed medication during their participation in this study \[exception: female subjects who are taking oral, patch, or intrauterine device (IUD) hormonal contraceptives, or progestin implant or injection\].
24\. Subject is a staff member or the relative of a staff member. 25. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or HbA1c ≥ 6.5% will be excluded.
26\. Subject has a prolactin concentration \> 100 ng/mL at screening or has a history of pituitary adenoma. NOTE: Subjects with prolactin levels \> 100 ng/mL and ≤ 200 ng/mL Protocol SEP361-201, Version 3.01 SEP-363856 Confidential and Proprietary 39 17 August 2017 at the Screening visit are permitted to enroll after discussion with the Medical Monitor to ensure exclusion of non-psychotropic drug-related causes of elevated prolactin levels.
27\. .Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Randomization Criteria
1. Subject must have a PANSS total score ≥ 80 at Baseline (Day 1).
2. Subject must have a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at Baseline (Day 1).3. Subject must have a CGI-S score ≥ 4 at Baseline (Day 1).
3. Subject must not demonstrate a decrease (improvement) of ≥ 20% in the PANSS total score between Screening and Baseline visits, or the PANSS total score falls below 80 at Baseline (Day 1).
4. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
5. Subject must have a total score \< 5 on the SAS at Baseline (Day 1).
6. Subject must not answer "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Baseline (ie, since last visit).
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woodland International Research Group
Little Rock, Arkansas, United States
Site Status
Collaborative Neuroscience Network, LLC
Garden Grove, California, United States
Site Status
California Neuropsychopharmacology Clinical Research Institute-LA, LLC(CNRI- LA, LLC)
Pico Rivera, California, United States
Site Status
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Site Status
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Site Status
Pillar Clinical Research, LLC
Richardson, Texas, United States
Site Status
Rehabilitacios Elmegyogyaszati osztaly
Gyöngyös, , Hungary
Site Status
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
Gyula, , Hungary
Site Status
Bucharest, , Romania
Site Status
Centrul de Evaluare si Tratament al Toxicodependentelor pentru Tineri "Sfantul Stelian" - C.E.T.T.T. "Sf. Stelian"
Bucharest, , Romania
Site Status
Spitalul Clinic de Neuropsihiatrie Craiova
Craiova, , Romania
Site Status
Institutul de Psihiatrie Socola Iasi, Sectia Clinica III Acuti, Sos. Bucium
Iași, , Romania
Site Status
State Budgetary Institution of Republic Karelia "Republican Psychiatric Hospital"
Matrosy, Republic Karelia, Russia
Site Status
Federal State Budgetary Scientific Instittuion "Scientific Center of Mental Health
Moscow, , Russia
Site Status
Saint Petersburg State Budgetary Institution of Healthcare "Psychiatric Hospital #1 named after P.P. Kashchenko"
Saint Petersburg, , Russia
Site Status
City Psychiatric Hospital of St. Nikolay Chudotvorets
Saint Petersburg, , Russia
Site Status
FSBI Saint Petersburg Scientifc and Research Psychoneurological Instatitute named after V.M Bekhterev
Saint Petersburg, , Russia
Site Status
SPHI "City Mental Hospital #3 n.a. I.I.Skvortsov-Stepanov"
Saint Petersburg, , Russia
Site Status
300173524
Saint Petersburg, , Russia
Site Status
300151369
Saratov, , Russia
Site Status
SBEI HPE "Smolensk State Medical University" of the MoH of the RF
Smolensk, , Russia
Site Status
300195230
Yekaterinburg, , Russia
Site Status
Ch of Psychiatry, Narcology and Med Psychol
Ivano-Frankivsk, , Ukraine
Site Status
Dept of Crisis Cond & Primary Psych Episode #1
Ivano-Frankivsk, , Ukraine
Site Status
Psychiatric Department of Primary Psychotic Episodes
Kharkiv, , Ukraine
Site Status
Unit of Emergency Psychiatry and Narcology
Kharkiv, , Ukraine
Site Status
Dept of Psychiarty #3 (male) and #10 (female)
Kherson, , Ukraine
Site Status
TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
Kyiv, , Ukraine
Site Status
CI Odesa Regional Medical Center of Mental Health
Odesa, , Ukraine
Site Status
Femal Dept #11, Male Dept #12
Smila, , Ukraine
Site Status
Ch of Neurology, Psychiatry, Narcology and MP
Ternopil, , Ukraine
Site Status
Dept of Psychiatry
Uzhhorod, , Ukraine
Site Status
Ch of Psychiatry and Narcology
Vinnytsia, , Ukraine
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Hungary
Romania
Russia
Ukraine
References
Explore related publications, articles, or registry entries linked to this study.
Halff EF, Rutigliano G, Garcia-Hidalgo A, Howes OD. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. doi: 10.1016/j.tins.2022.10.010. Epub 2022 Nov 8.
Reference Type
DERIVED
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. N Engl J Med. 2020 Apr 16;382(16):1497-1506. doi: 10.1056/NEJMoa1911772.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-001555-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SEP361-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
NCT05848700
COMPLETED
PHASE1
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212
RECRUITING
PHASE3
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
NCT01393613
COMPLETED
PHASE3
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
NCT05542264
COMPLETED
PHASE1
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
NCT01397786
COMPLETED
PHASE3
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
NCT01451164
COMPLETED
PHASE2/PHASE3
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281
COMPLETED
PHASE3
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
NCT03351244
TERMINATED
PHASE2
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
NCT04038957
COMPLETED
PHASE1
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
NCT00905307
COMPLETED
PHASE2
Multicenter, Open-label, Safety and Tolerability Study
NCT01649557
COMPLETED
PHASE2
SB-773812 Administered In Adults With Schizophrenia
NCT00259870
COMPLETED
PHASE2
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
NCT01396421
COMPLETED
PHASE3
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
NCT01952132
COMPLETED
PHASE2
A Long-term Trial of OPC-34712 in Patients With Schizophrenia
NCT01456897
COMPLETED
PHASE3
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
NCT00212797
COMPLETED
PHASE2
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
NCT00728195
COMPLETED
PHASE2
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
NCT01518894
COMPLETED
PHASE1
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
NCT05402111
COMPLETED
PHASE1
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
NCT02281773
COMPLETED
PHASE2
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
NCT01829048
COMPLETED
PHASE1
Phase IIA Study in Patients With Schizophrenia
NCT00686998
COMPLETED
PHASE2
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
NCT01429740
COMPLETED
PHASE1